Race Oncology (ASX:RAC) has completed the dose escalation stage of its Phase 1b/2 Zantrene study into ALM (acute myeloid leukemia) and is now set to progress to the Phase 2 efficacy (expansion) stage using a four-day schedule of Zantrene, in…